RxDoctor Payments Data

Seema Mohan, MD

Internal Medicine · Carefree, AZNPI 1588604177

Payments from drug & device makers

$2,552in general payments, 2019–2025

Across 94 payments — averaging $27.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$406
  • AbbVie$370
  • Pfizer$197
  • Boston Scientific$188
  • Shockwave Medical, Inc$165
  • Lilly USA, LLC$152
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,552100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,552 in reported general payments places this provider in the 85th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$62,030
Medicare patients
105
Services billed
756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$41,259
MounjaroTirzepatide27$37,609
TrulicityDulaglutide17$31,757
SynthroidLevothyroxine Sodium61$5,208
Rosuvastatin Calcium277$3,449
Levothyroxine Sodium359$3,324
ShingrixVaricella-Zoster Ge/As01b/Pf14$3,111
Ibandronate Sodium83$3,039
Atorvastatin Calcium245$2,322
Nebivolol Hcl20$2,223
Armour ThyroidThyroid,pork21$1,823
Mirtazapine40$1,569
Losartan Potassium155$1,449
Montelukast Sodium72$1,353
Escitalopram Oxalate80$1,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$152$69,36644 claims
PfizerEliquis$197$41,25929 claims
AbbVieSynthroid, Armour Thyroid$370$7,03182 claims
GSKShingrix$73$3,11114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Carefree

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →